TSC の発症と進行を止める 2B: シロリムス TSC てんかん予防研究 (TSC-STEPS)
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.
This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
調査の概要
詳細な説明
Tuberous Sclerosis Complex (TSC) is caused by genetic mutation in TSC1 or TSC2, resulting in dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway. Age at time of seizure onset in TSC infants has been linked to long-term neurodevelopmental outcome in this high-risk population. Sirolimus is an mTOR inhibitor used to treat many of the symptoms of TSC, including epilepsy. This will be the first study to truly evaluate a targeted, disease-modifying drug therapy for preventing or delaying seizure onset in TSC using a rational, mechanism-based therapeutic approach.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- University of Alabama at Birmingham
-
-
California
-
Los Angeles、California、アメリカ、90095
- University of California at Los Angeles
-
Palo Alto、California、アメリカ、94304
- Stanford University
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Boston Children's Hospital
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27510
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston、Texas、アメリカ、77030
- University of Texas HSC at Houston
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- Seattle Children's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 0-6 months of age at the time of enrollment (subject must be <7 months of chronological age at time of randomization and treatment initiation). Corrected age must be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).
- Has a confirmed diagnosis of TSC based on established clinical or genetic criteria
Exclusion Criteria:
- Prior history of seizures (clinical or electrographic) at the time of enrollment or identified on baseline EEG.
- Has been treated in the past or is currently being treated at the time of enrollment with conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or another anti-seizure therapeutic agent, device, or procedure.
- Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.
- Has a significant illness or active infection at the time of the baseline screening visit
- Has a history of significant prematurity, defined as gestational age <30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that other than TSC would convey additional risk of seizures or neurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery, prolonged ventilatory or other life-saving supportive care or procedures).
- Abnormal laboratory values at baseline (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject.
- Prior, planned or anticipated neurosurgery within 3 months of the baseline visit
- Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).
- Subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Placebo |
Matching placebo |
|
実験的:Sirolimus
Sirolimus |
The investigational drug product to be used in this study is sirolimus, provided in oral suspension. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacy -- time to seizure onset
時間枠:12 months of age
|
Time to seizure onset, comparing sirolimus with placebo |
12 months of age
|
|
Safety -- adverse events
時間枠:12 months of age
|
Percentage of subjects reporting severe (CTCAE v5.0 grade >= 3) adverse event (AE) or serious adverse event (SAE), comparing sirolimus with placebo. |
12 months of age
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Neurodevelopmental Outcomes
時間枠:12 and 24 months of age
|
Neurodevelopmental outcomes at the end of treatment, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
Quality of Life Outcomes
時間枠:12 and 24 months of age
|
Patient and caregiver quality of life, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
EEG Biomarkers
時間枠:12 and 24 months of age
|
EEG measures of neuronal connectivity, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
MRI Biomarkers
時間枠:12 and 24 months of age
|
MRI measures of neuronal connectivity, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
Sirolimus Precision Dosing
時間枠:12 months of age
|
Validate the feasibility and effectiveness of sirolimus precision dosing in infants with TSC |
12 months of age
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Darcy A Krueger, MD, PhD、Children's Hospital Medical Center, Cincinnati
- 主任研究者:Martina Bebin, MD, MPA、University of Alabama at Birmingham
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2021-0438
- 1R01FD007275 (米国FDA認可/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。